Company Encyclopedia
View More
name
Dyadic
DYAI.US
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells industrial enzymes and other proteins in the United States and internationally. It utilizes the C1 platform in pharmaceutical applications, including the development and production of pharmaceutical products. The company offers Dapibus, a protein production platform that enable the rapid development and large-scale manufacture of cost-effective enzymes, proteins, metabolites, and other biologic products for life sciences, food and nutrition, and bioindustrial applications. In addition, it develops DYAI-100, a C1-SARS-CoV-2 recombinant protein RBD vaccine candidate and first C1, which is in phase 1 clinical trial to produce protein tested in humans.
1.946 T
DYAI.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking302/394
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-244.15%E
    • Profit Margin-219.86%E
    • Gross Margin12.07%D
  • Growth ScoreD
    • Revenue YoY-0.66%D
    • Net Profit YoY-16.08%D
    • Total Assets YoY8.02%B
    • Net Assets YoY-23.59%E
  • Cash ScoreD
    • Cash Flow Margin-45.48%D
    • OCF YoY-0.66%D
  • Operating ScoreD
    • Turnover0.3D
  • Debt ScoreE
    • Gearing Ratio77.66%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    U.S. stock night trading volatility: Dyadic's collaboration with Brig Bio failed to boost stock prices, dropping 8.03% in night trading

    Dyadic fell 8.03% in the after-hours market; Janux Therapeutics fell 44.19% in the after-hours market, with a trading volume of USD 361,900; Q32 Bio fell 2.09% in the after-hours market, with a trading volume of USD 319,200; Recursion Pharmaceuticals rose 1.38% in the after-hours market, with a trading volume of USD 302,700

    Tracking Unusual Activity·
    US
    DYAI
    +6.11%
    Tracking Unusual Activity·
    US
    DYAI
    +6.11%

    Dyadic International shares are trading higher after the company announced it signed a Development and Commercialization Agreement with BRIG Bio to jointly develop and commercialize recombinant bovine alpha-lactalbumin.

    benzinga_article·
    US
    DYAI
    +6.11%
    benzinga_article·
    US
    DYAI
    +6.11%

    Dyadic International Inc - Co And Brig Bio Sign Development And Commercialization Agreement

    DYADIC INTERNATIONAL INC - CO AND BRIG BIO SIGN DEVELOPMENT AND COMMERCIALIZATION AGREEMENTDYADIC INTERNATIONAL INC - BRIG BIO TO FUND DEVELOPMENT, DYADIC TO RECEIVE MILESTONE PAYMENTS

    Reuters·
    US
    DYAI
    +6.11%
    Reuters·
    US
    DYAI
    +6.11%

    Dyadic International and BRIG BIO Sign Agreement to Develop Animal-Free Bovine Alpha-Lactalbumin

    Dyadic International Inc. and BRIG BIO have signed an agreement to develop and commercialize animal-free bovine alpha-lactalbumin. BRIG BIO will fund the development and receive a global license to Dyadic's production strains. Dyadic will receive milestone payments, shared revenue, and co-marketing rights. The partnership aims to enhance the production and availability of alpha-lactalbumin for nutrition markets.

    Reuters·
    US
    DYAI
    +6.11%
    Reuters·
    US
    DYAI
    +6.11%

    Dyadic International’s Earnings Call: Cautious Optimism Amid Challenges

    Dyadic International Inc.'s Q3 earnings call revealed cautious optimism amid financial challenges. The company achieved its first commercial bulk sale and secured strategic partnerships, signaling growth. However, revenue declined to $1.165 million, and net loss increased to $1.976 million. Dyadic rebranded as Dyadic Applied Biosolutions, launched a new website, and secured a CRISPR Cas9 license. It received $1.5 million in milestone payments and partnered with Intralink for Asian market expansion. Despite financial hurdles, Dyadic remains focused on growth opportunities in life sciences and food nutrition segments.

    Tip Ranks·
    US
    DYAI
    +6.11%
    Tip Ranks·
    US
    DYAI
    +6.11%
    © 2025 Longbridge｜Disclaimer